ArticleClinical and experimental medicine2026
Increased glioblastoma risk in patients with myeloproliferative neoplasms and myelodysplastic syndromes.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted therapies significantly extend the survival of patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS). This prolonged lifespan introduces an unintended clinical hazard. These patients face an elevated risk of developing primary central nervous system (CNS) tumors. The internal relationship between them remains to be explored. We integrated the Global Burden of Disease (GBD) and the Cancer Incidence in Five Continents (CI5) datasets to conduct spatial clustering mapping using Moran's I. Vector autoregression and Granger causality analysis were employed to examine the longitudinal incidence of these diseases in Sweden from 1990 to 2021. Bibliometric profiling was utilized to identify research frontiers, and two-sample Mendelian randomization (MR) was used to determine genetic correlation. Geospatial mapping indicated a dually dominant burden of MPN + MDS (MPN and MDS, not MPN/MDS) and CNS tumors in developed regions. Longitudinal data from Sweden exposed a strictly unidirectional predictive trajectory exclusive to females. Myeloid malignancies reliably preceded CNS tumors. Bibliometric analysis demonstrated a remarkable interdecadal convergence on neuroinflammation and the tumor microenvironment. Significantly, MR confirmed that MPN (odds ratio [OR] = 1.84, 95% confidence interval [CI]: 1.22-2.76) and MDS (OR = 2.54, 95% CI: 1.62-3.96) have definite positive effects on GBM susceptibility. We established the possible comorbidity relationship between MPN + MDS and GBM, and raised the myeloid-neuro-immune crosstalk theory. It lays a reliable foundation on the interactions between MPN + MDS and GBM for future research, and offers insights for building multidisciplinary team collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.